<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2021-34-24-28</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-2341</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Оценка эффективности сочетанного использования КОК и наружного препарата, содержащего азелаиновую кислоту, в терапии акне</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of effectiveness of combined use of COC and topical preparation containing azelaic acid for acne</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5044-5265</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Круглова</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruglova</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Круглова Лариса Сергеевна, д. м. н., проф., проректор по учебной работе, зав. кафедрой дерматовенерологии и косметологии</p><p>Москва</p><p>eLibrary SPIN: 1107–4372</p></bio><bio xml:lang="en"><p>Kruglova Larisa S., DM Sci (habil.), professor, vice-rector for academic affairs, head of Dept of Dermatovenereology and Cosmetology</p><p>Moscow</p><p>eLibrary SPIN: 1107–4372</p></bio><email xlink:type="simple">kruglovals@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3437-5233</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грязева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gryazeva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грязева Наталья Владимировна, к. м. н., доцент кафедрыдерматовенерологии и косметологии</p><p>Москва</p><p>eLibrary SPIN: 1309–4668</p></bio><bio xml:lang="en"><p>Gryazeva Natalia V., PhD Med, associate professor at Deptof Dermatovenereology and Cosmetology</p><p>Moscow</p><p>eLibrary SPIN: 1309–4668</p></bio><email xlink:type="simple">tynrik@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central State Medical Academy of the Administrative Department of the President of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2021</year></pub-date><volume>0</volume><issue>34</issue><issue-title>Дерматология (3)</issue-title><fpage>24</fpage><lpage>28</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Круглова Л.С., Грязева Н.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Круглова Л.С., Грязева Н.В.</copyright-holder><copyright-holder xml:lang="en">Kruglova L.S., Gryazeva N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/2341">https://www.med-alphabet.com/jour/article/view/2341</self-uri><abstract><p>В статье представлены результаты оценки эффективности сочетанного использования КОК и крема Скинорен при тяжелом папуло- пустулезном и умеренном узловато-кистозном акне.</p><sec><title>Материал и методы</title><p>Материал и методы. Пациенты первой группы (n = 11) использовали для лечения акне КОК и наружный антибактериальный препарат два раза в сутки. Пациенты второй группы (n = 12) использовали для лечения акне КОК и наружный препарат, содержащий азелаиновую кислоту (Скинорен) два раза в сутки. Продолжительность наблюдения составила 6 месяцев. Оценка эффективности проводилась с учетом динамики показателей шкалы IGA (Investigators Global Assessment). Для оценки эффективности коррекции постакне использовалась Манчестерская шкала оценки рубцовых деформаций (Manchester Scar Scale, MSS). Кроме того, оценка эффективности проводилась по результатам мексаметрии.</p></sec><sec><title>Результаты</title><p>Результаты. При оценке IGA в группах сравнения у больных с тяжелым папулопустулезным акне и умеренным узловато-кистозным акне отмечалась сопоставимая эффективность, однако лучшие результаты зафиксированы в группе «КОК + Скинорен» (р &lt; 0,05). Отсутствие эффекта и ухудшение состояния ни в одной группе не наблюдалось. При оценке MSS наиболее выраженные изменения отмечались у пациентов группы 2, где использовалась комбинация КОК + Скинорен. Так, в группе 1 выраженность рубцов уменьшилась на 42,3 %, во 2-й – на 48,2 % (p &lt; 0,05). Оценка результатов мексаметрии показала более выраженное снижение количества пигмента у пациентов из группы 2. При изучении результатов выраженности эритемы получена динамика, сходная с выраженностью пигмента. Наилучший результат зарегистрирован в группе 2 («КОК + Скинорен») (р &lt; 0,05).</p></sec><sec><title>Выводы</title><p>Выводы. Комбинированное использование КОК и крема Скинорен при тяжелом папуло-пустелезном и умеренном узловато-кистозном акне зарекомендовало себя как эффективный метод и в отношении количества воспалительных и ретенционных элементов, и в отношении гиперпигментации.</p></sec></abstract><trans-abstract xml:lang="en"><p>The article presents the results of evaluating the effectiveness of the combined use of combined oral contraceptives (COC) and Skinoren cream in severe papular-pustular and moderate nodular-cystic acne.</p><sec><title>Material and methods</title><p>Material and methods. Patients of the first group (n = 11) used COC and an external antibacterial drug two times a day for the treatment of acne. Patients of the second group (n = 12) used COC and an external drug containing azelaic acid (Skinoren) for the treatment of acne two times a day. The duration of follow-up was 6 months. The efficiency assessment was carried out taking into account the dynamics of the indicators of the IGA (Investors Global Assessment) scale. The Manchester Scar Scale (MSS) was used to assess the effectiveness of post-acne correction. In addition, the effectiveness was evaluated based on the results of the mexametry.</p></sec><sec><title>Results</title><p>Results. When evaluating IGA in the comparison groups in patients with severe papulopustular acne and moderate nodular cystic acne, comparable efficacy was noted, but the best results were recorded in the COC + Skinoren group (p &lt; 0.05). No effect and deterioration of the condition were observed in any group. When assessing MSS, the most pronounced changes were observed in patients of group 2, where the combination of COC + Skinoren was used. So, in group 1, the severity of scars decreased by 42.3 %, in group 2 by 48.2 % (p &lt; 0.05). The evaluation of the results of the mexametry showed a more pronounced decrease in the amount of pigment in patients from group 2. When studying the results of the severity of erythema, the dynamics similar to the severity of the pigment was obtained. The best result was registered in group 2 (COC + Skinoren) (p &lt; 0.05).</p></sec><sec><title>Conclusions</title><p>Conclusions. The combined use of COC and Skinoren cream for severe papular-pustular and moderate nodular-cystic acne has proven to be an effective method both in relation to the number of inflammatory and retention elements, and in relation to hyperpigmentation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>акне</kwd><kwd>гиперпигментация</kwd><kwd>комбинированные оральные контрацептивы</kwd><kwd>азелаиновая кислота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acne</kwd><kwd>hyperpigmentation</kwd><kwd>combined oral contraceptives</kwd><kwd>azelaic acid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lakshmi C. Hormone therapy in acne. Indian J Dermatol Venereol Leprol. 2013; 79: 322–337.</mixed-citation><mixed-citation xml:lang="en">Lakshmi C. Hormone therapy in acne. Indian J Dermatol Venereol Leprol. 2013; 79: 322–337.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004; 22 (5): 419–428.</mixed-citation><mixed-citation xml:lang="en">Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004; 22 (5): 419–428.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tyler KH, Zirwas MJ. Pregnancy and dermatologic therapy. J Am Acad Dermatol. 2013; 68 (4): 663–671.</mixed-citation><mixed-citation xml:lang="en">Tyler KH, Zirwas MJ. Pregnancy and dermatologic therapy. J Am Acad Dermatol. 2013; 68 (4): 663–671.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nast A, Dreno B, Bettoli V, et al. European evidence-based (S 3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012; 26: 1–29.</mixed-citation><mixed-citation xml:lang="en">Nast A, Dreno B, Bettoli V, et al. European evidence-based (S 3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012; 26: 1–29.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Harper JC. Use of oral contraceptives for management of acne vulgaris: practical considerations in real world practice. Dermatol Clin. 2016; 34 (2): 159–165.</mixed-citation><mixed-citation xml:lang="en">Harper JC. Use of oral contraceptives for management of acne vulgaris: practical considerations in real world practice. Dermatol Clin. 2016; 34 (2): 159–165.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gollnick HP, Dreno B. Pathophysiology and management of acne. J Eur Acad Dermatol Venereol. 2015; 29 (suppl 4): 1–2.</mixed-citation><mixed-citation xml:lang="en">Gollnick HP, Dreno B. Pathophysiology and management of acne. J Eur Acad Dermatol Venereol. 2015; 29 (suppl 4): 1–2.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Arrington EA, Patel NS, Geranker K, Feldman SR. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis. 2012; 90 (2):83–90.</mixed-citation><mixed-citation xml:lang="en">Arrington EA, Patel NS, Geranker K, Feldman SR. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis. 2012; 90 (2):83–90.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lakshmi C. Hormone therapy in acne. Indian J Dermatol Venereol Leprol. 2013; 79: 322–337.</mixed-citation><mixed-citation xml:lang="en">Lakshmi C. Hormone therapy in acne. Indian J Dermatol Venereol Leprol. 2013; 79: 322–337.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg. 2008; 27 (3): 188–196.</mixed-citation><mixed-citation xml:lang="en">George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg. 2008; 27 (3): 188–196.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Husein-ElAhmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatol Ther. 2015; 28 (3): 166–172.</mixed-citation><mixed-citation xml:lang="en">Husein-ElAhmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatol Ther. 2015; 28 (3): 166–172.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Harper JC. Use of oral contraceptives for management of acne vulgaris: practical considerations in real world practice. Dermatol Clin. 2016; 34 (2): 159–165.</mixed-citation><mixed-citation xml:lang="en">Harper JC. Use of oral contraceptives for management of acne vulgaris: practical considerations in real world practice. Dermatol Clin. 2016; 34 (2): 159–165.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Arrington EA, Patel NS, Geranker K, Feldman SR. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis. 2012; 90 (2): 83–90.</mixed-citation><mixed-citation xml:lang="en">Arrington EA, Patel NS, Geranker K, Feldman SR. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis. 2012; 90 (2): 83–90.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chan CS, Harting M, Rosen T. Systemic and barrier contraceptives for the dermatologist: a review. Int J Dermatol. 2009; 48: 795–814.</mixed-citation><mixed-citation xml:lang="en">Chan CS, Harting M, Rosen T. Systemic and barrier contraceptives for the dermatologist: a review. Int J Dermatol. 2009; 48: 795–814.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Filoni A., Mariano M., Cameli N. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol. 2019 Apr; 18 (2): 458–463.</mixed-citation><mixed-citation xml:lang="en">Filoni A., Mariano M., Cameli N. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol. 2019 Apr; 18 (2): 458–463.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
